Meeting
2022 ASCO Genitourinary Cancers Symposium
The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.
Authors
Esmail Mutahar Al-Ezzi
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
Esmail Mutahar Al-Ezzi , Abhenil Mittal , Brooke Wilson , Marco Iafolla , Pavlina Spiliopoulou , Srikala S. Sridhar , Nazanin Fallah-Rad , Peter W. M. Chung , Nathan Perlis , Aaron Richard Hansen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 333)
DOI
10.1200/JCO.2022.40.6_suppl.333
Abstract #
333
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.
First Author: Esmail Mutahar Al-Ezzi
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population.
First Author: Angela Strambi
Poster
2016 Genitourinary Cancers Symposium
The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.
First Author: Haoran Li
Poster
2024 ASCO Breakthrough
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer: A multicenter study.
First Author: Fumihiko Urabe